Laurie Barclay, MD
NEW YORK (MedscapeWire) Apr 26 The antisense oligonucleotide fomivirsen is reasonably safe and effective in treating CMV retinitis in AIDS patients, according to the results of 3 trials by the Vitravene Study Group and an accompanying editorial in the April issue of the American Journal of Ophthalmology.
"Cytomegalovirus (CMV) retinitis is among the most common opportunistic infections in patients with the acquired immunodeficiency syndrome (AIDS)," write D. A. Jabs and P. D. Griffiths, from Johns Hopkins University School of Medicine, Baltimore, Maryland, in an editorial. "There is an ongoing need for treatment options…for patients who develop CMV resistance to initial therapy."
As of September 2001, 4 drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of CMV retinitis: ganciclovir, foscarnet, cidofovir, and fomivirsen. Ganciclovir is available as an intravenous (IV) or oral formulation, as a sustained release implant surgically placed in the eye, and as a prodrug (valganciclovir) with improved gastrointestinal absorption. Foscarnet and cidofovir are available only as IV formulations and fomivirsen only as a formulation for intravitreous injections.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!